GLP-1 agonists can play a pivotal role in disrupting the vicious cycle of obesity by supporting the growth of beneficial gut bacteria, which enhances gut mucosal integrity [47] and optimizes nutrient availability [48]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.